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ABSTRACT
In mice transgenesis through oocyte injection or DNA
recombination in embryonal stem (ES) cells allows
mutations to be introduced into the germline. However,
the earliest phenotype of the introduced mutation can
eclipse later effects. We show in mice that site-specific
genomic recombination can be induced in a selected
cell type, B lymphocytes, at a chosen time. This
precision of somatic mutagenesis was accomplished
by limiting expression of a Cre recombinase–estrogen
receptor fusion protein to B lymphocytes by use of
tissue-specific elements in the promoter of the trans-
gene employed. The expressed fusion protein
remained inactive until derepressed by systemic
administration of an exogenous ligand for the estrogen
receptor, 4-OH-tamoxifen. Upon derepression the Cre
recombinase enzyme deleted specific DNA segments,
flanked by loxP sites, in B lymphocytes only. The
efficiency of recombination in cells expressing the
fusion protein could be varied from low levels to >80%,
depending on the dose of ligand administered. Our
work presents a paradigm applicable to other uses of
site-specific recombination in somatic mutagenesis
where both temporal and spatial regulation are desired.
INTRODUCTION
Regulated somatic mutagenesis is essential for the analysis of
gene function during development and in the mature organism. In
mice transgenesis through oocyte injection or DNA recombination
in embryonal stem (ES) cells allows mutations to be introduced into
the germline. However, the earliest phenotype of the introduced
mutation can eclipse later effects. Somatic mutagenesis is essential
for studies of gene function during subsequent development.
Recent work on somatic mutagenesis has focused on the use of
site-specific recombination (1–3). Two site-specific recombinases
(SSRs), Cre recombinase from the Escherichia coli phage P1 and
FLP recombinase from the 2µ circle of Saccharomyces cerevisiae,
have been shown to possess the properties required for genomic
manipulations in a wide range of living systems, including mice,
plants and flies. Genomic manipulations with SSRs require
expression of an SSR protein and introduction of at least two
recombination target sites at chosen positions in the genome. The
type of recombination event mediated by the SSR depends on the
disposition of the recombination target sites, with deletions,
inversions, translocations and integrations being possible (1).
Previously we showed that the ligand-dependent characteristics of
steroid hormone receptors can be imposed on FLP recombinase
by expressing FLP recombinase–steroid receptor fusion proteins
(4). These fusion recombinases are inactive in the absence of a
cognate steroid hormone, but respond rapidly to hormone
administration. Ligand dependency can be similarly imposed on
Cre recombinase (5–7). Thus SSR–steroid receptor fusion
proteins present an experimentally convenient way to determine
the time of recombination by ligand administration.
Somatic mutagenesis in mice using SSRs requires, for precision,
a near complete absence of background recombination, both in
cell types other than the target tissue and before the chosen time
of induction. To accomplish the first of these two objectives we
restricted expression of Cre recombinase to a given cell type by
use of a tissue-specific promoter, since previous work in mice has
shown effective spatial regulation of recombination based on this
strategy (8–11). To accomplish the second, Cre was expressed as
a fusion protein with a mutant estrogen receptor ligand binding
domain (EBD) that is insensitive to the endogenous hormone
β-estradiol but still responsive to the synthetic estrogen antagonist
4-OH-tamoxifen. Thus two levels of regulation, spatial and
temporal, were combined in a single transgene (Fig. 1).
MATERIALS AND METHODS
DNA constructs
To generate the CreED4 coding sequence the stop codon of the
Cre reading frame was replaced by the linker peptide VRGS and
then fused to amino acid 304 of the human estrogen receptor. The
pgkCreED4 vector was derived from the plasmid pgk-neo-bpA
through replacement of the neo gene by the Cre–EBD coding
sequence. To construct the Eµ/PSV40 Cre–EBD(G521R) expression
vector the 2.0 kb SmaI–XhoI fragment from p44CreEBD-4,
which contains Cre fused to the EBD(G521R) coding region
(P.-O.Angrand, unpublished results), was ligated into the poly-
linker of pEµhGH (F.Schwenk, unpublished results).
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Figure 1. Principle of combinatorial temporal and spatial regulation of site-specific
recombination in mice. (1) Expression of a site-specific recombinase–nuclear
receptor ligand binding domain (SSR–LBD) fusion protein is directed to a chosen
cell type by the properties of the cis regulatory elements of the transgene. In this
case the immunoglobulin heavy chain enhancer (Eµ) is combined with the
SV40 early minimal promoter to direct transgene expression exclusively to B
lymphocytes. (2) The expressed protein is a fusion of Cre recombinase and the
estrogen binding domain (EBD) of the human estrogen receptor mutated at amino
acid 521 (G521R). The Cre–EBD(G521R) protein is inactive because the EBD
interacts with the ubiquitous Hsp90 complex. The fusion protein is released from
the inactive state upon ligand binding by the LBD, allowing recombination
between two loxP sites present in the genome. Hsp, heat shock protein.
Transgenic cells
The SV40-transformed murine embryonic fibroblast line
MEF5/5 (M.Aguet, unpublished results) was transfected with the
vector pl2neo (H.Gu, unpublished results), which contains an
HSVtk promoter-driven neo gene flanked by two loxP sites and,
on one side, DNA from the yeast leu2 gene. A single copy
integrant, identified by Southern blotting, was further transfected
with a hygromycin resistance vector together with the Cre–
EBD(521R) expression vector pgkCreED4. In all of the four
stable transfectants analyzed (containing 3–10 copies of
pgkCreED4) Cre activity was induced upon administration of
anti-hormone, although to different extents. Clone 4-4 was most
efficient and was used for further analysis. Cre activity was
measured by Southern blotting of XbaI-digested genomic DNA
using the adjacent leu2 probe. Cre-mediated deletion reduces the
band detected by the leu2 probe by 1.2 kb.
Transgenic mice
Transgenic mice were produced by pronuclear injection of the
purified DNA fragment into fertilized (C57Bl/6 × CBA) F2 eggs
using standard techniques. Founder mice were screened for
Cre–EBD(G521R) expression using the anti-Cre mAB 7.23 (12).
Of 14 transgenic mice generated, two showed detectable expression
of Cre–EBD(G521R) in B cells.
Ligand administration
Aliquots of 50 mg 4-OH-tamoxifen (Sigma H-6278) were
dispersed in 1.5 ml sunflower seed oil with a sonicator. Aliquots
were shock frozen and stored at –80C. After thawing the
samples were heated for 5 min at 60C and injected i.p. through
a 26 gauge needle. On gross inspection of the organs of mice
treated with 4-OH-tamoxifen (five injections of 8 mg) no
abnormalities compared with non-treated controls were found. In
bone marrow, spleen and thymus of 4-OH-tamoxifen-treated
mice the populations of immature and mature B and T cells
appeared normal by flow cytometric analysis.
RESULTS
Ligand-dependant recombination in a fibroblast cell line
The Cre enzyme was expressed as a fusion protein with a mutant
human estrogen receptor ligand binding domain, EBD(G521R). The
equivalent GlyArg mutation in the mouse estrogen receptor
(G525R) renders this EBD resistant to activation by the natural
estrogen receptor agonist β-estradiol, while allowing activation by
the synthetic antagonist 4-OH-tamoxifen (13,14). Cre–
EBD(G521R) fusion proteins were first tested in a stable cell assay
to evaluate regulatory properties and further characterize the
response of the G521R mutation to other estrogens. A fibroblast cell
line containing a single copy of a neomycin resistance gene flanked
by the loxP target sites for Cre recombinase (‘floxed’) was
transfected with Cre–EBD(G521R) constructs (Fig. 2A) and stable
clones isolated. Constitutive expression of Cre–EBD(G521R) did
not result in detectable recombination when the cells were grown for
up to 4 days in medium alone (Fig. 2B and C). As expected from
the known properties of the G525R mutation, addition of high
concentrations of β-estradiol resulted in only a very weak induction
of recombination, whereas 4-OH-tamoxifen induced near complete
recombination (Fig. 2B). Cre–EBD(G521R) was insensitive to the
second major endogenous mammalian estrogen, estriol, whilst
responding efficiently to another synthetic antagonist, raloxifen
(Fig. 2B). The synthetic antagonist nafoxidine (Fig. 2B) and the
synthetic agonists diethylstilbesterol and hexesterol also did not
induce recombination, whereas ICI 182,780 did (data not shown).
Both raloxifen (Fig. 2C) and 4-OH-tamoxifen (data not shown)
induced recombination with reasonable and equivalent kinetics.
Titration experiments with 4-OH-tamoxifen (Fig 2D), raloxifen or
ICI 182,780 (data not shown) showed that Cre–EBD(G521R)
displays ∼100 times less apparent affinity for these ligands than
expected from the affinities of the natural estrogen receptor for these
ligands. Nevertheless, the Cre–EBD(G521R) protein used here
shows the necessary properties of low background recombination,
insensitivity to endogenous mammalian estrogens and efficient
inducibility by several synthetic antagonists.
Previous work has indicated that ligand regulation of steroid
receptor fusion proteins differs according to the length of linker
peptide between the protein to be regulated and the ligand binding
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Figure 2. Characteristics of ligand-dependent recombination mediated by
Cre–EBD(G521R) in a fibroblast cell line. (A) The transgene used to express
Cre–EBD(G521R) constitutively and the floxed neomycin cassette (neo) stably
integrated as a single copy in a fibroblast cell line are depicted. The
Cre–EBD(G521R) fusion is composed of amino acids 303–595 of the human
estrogen receptor with a GR mutation at position 521. Cre-mediated deletion
of the loxP-flanked neo gene was detected by Southern blot analysis of XbaI
(X)-digested genomic DNA using the indicated probe. Upon Cre-mediated
deletion the band detected by the probe is reduced by 1.2 kb. (B) Southern blot
analysis of Cre–EBD(G521R)-mediated gene deletion upon treatment with
various ligands. Transfectant 4-4 was cultured for 4 days in medium alone or
in medium containing estradiol (0.1 µM), raloxifen (0.5 µM), nafoxidin
(0.1 µM), 4-OH-tamoxifen (0.1 µM) or estriol (100 µM). Cre-mediated
deletion reached 90% upon induction with 4-OH-tamoxifen and raloxifen, as
measured with a Fuji BAS 1000 Bio-Imaging Analyzer. (C) Time course of
ligand-induced recombination in transfectant 4-4. Cells were cultured for the
indicated number of days in medium alone or in medium containing 0.1 µM
estradiol or raloxifen. (D) Titration of 4-OH-tamoxifen-induced recombination
measured by quantification of Southern blots after 2 days induction.
Figure 3. Characteristics of the Cre–EBD transgene and its expression.
(A) Scheme of the transgene. The Cre–EBD(G521R) gene is expressed under
control of the immunoglobulin heavy chain enhancer (Eµ) and the SV40 early
minimal promoter (17). A 2.1 kb fragment of the human growth hormone gene
(hGH) provides splicing and polyadenylation signals (18). (B) Flow cytometric
analysis of Cre–EBD(G521R) expression in peripheral blood lymphocytes.
Lymphocytes from wild-type (wt) and CreED-30 mice were isolated and
stained intracellularly with the anti-Cre monoclonal antibody 7.23 (12) and for
IgM on the cell surface. Quantitated Cre expression in IgM-positive B cells and
IgM-negative non-B cells from wild-type (dashed lines) and Cre-ED-30 mice
(solid lines) is shown below. (C) Strategy to distinguish the DNA polymerase
β wild-type (upper line), loxP-flanked (middle line) and deleted (lower line)
alleles. The promoter region (ellipses), the first two exons of the polβ gene
(black rectangles) and an adjacent probe used for hybridization (bar) are shown.
In the polβflox allele a 1.5 kb gene segment has been flanked by two loxP sites
(triangles). The wild-type, loxP-flanked and deleted polβ alleles are represented
by BamHI (B) fragments of 10, 4.5 and 3 kb respectively.
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domain of the steroid receptor (5,15,16). Therefore, we tested two
Cre–EBD(G521R) fusion proteins. In addition to the one
employed here (composed of amino acids 303–595 of the human
estrogen receptor), a fusion protein that additionally included
estrogen receptor amino acids 252–303 between Cre and the EBD
was tested. This longer fusion protein showed significant
recombination in the absence of added ligand in both the stable
fibroblast cell system and transgenic mice (data not shown).
Generation of Cre–EBD(G521R) transgenic mice
Mice transgenic for the Eµ/PSV40 Cre–EBD(G521R) construct
illustrated in Figure 3A were established. Expression of the Cre
transgene was limited to B lymphocytes by placing it under
control of the immunoglobulin heavy chain enhancer (Eµ) linked
to a minimal SV40 promoter (17). Of 14 lines two expressed
Cre–EBD(G521R) only in B lymphocytes (strains CreED-24 and
CreED-30) and showed similar properties of expression and
ligand regulation. FACS analysis of Cre–EBD(G521R) expression
in CreED-24 and CreED-30 peripheral blood lymphocytes
showed that 75 ± 5% of IgM+ cells expressed Cre (Fig. 3B and
data not shown). Thus the Eµ/PSV40 Cre–EBD(G521R) transgene
delivered mosaic expression to the B lymphocytes of the
CreED-24 and CreED-30 strains.
Ligand-inducible, B cell-specific gene deletion in mice
The CreED-30 mouse line was crossed with a mouse line carrying
a floxed allele of the DNA polymerase β gene (polβflox; 9). This
allele was chosen because its heterozygotic deletion in B cells
shows no deleterious effects on cell survival, thereby permitting
analyses of recombination uncomplicated by cellular selection.
This was important, since we wanted to detect background
recombination that might occur in the absence of ligand
induction. No recombination was detected in B lymphocytes
before ligand induction by Southern analysis (Fig. 4A–C).
However, a low amont of background recombination (less than
∼1% total theoretical deletion of the floxed allele) in B
lymphocytes before ligand induction could be detected by PCR
(data not shown).
Ligand-inducible activation of Cre was tested in polβflox
heterozygotes (Fig. 4A–D) and homozygotes (Fig 4D). Ligand
was administered by daily i.p. injections of 0–8 mg ligand
solubilized in oil. A variety of experiments showed that maximal
recombination plateaued at ∼65% and that dosages of >4 mg/injec-
tion were not saturating. Five consecutive daily injections of 1, 2, 4
or 8 mg produced 17, 44, 62 or 64% recombination (Fig. 4A).
Analysis of different mice showed that percent induced
recombination with different administration protocols was
accurately reproducible (Fig. 4B). A single injection of apparently
saturating concentrations of 4-OH-tamoxifen (5 mg) induced 16%
recombination of the floxed allele (Fig. 4C). Further injections
induced more recombination up to a maximum of ∼65% within
5 days (Fig. 4C). Induction kinetics elicited by 4-OH-tamoxifen
or raloxifen were very similar (data not shown). No recombination
was detected in any tissue other than B lymphocytes in mice
treated with 4-OH-tamoxifen (Fig. 4E and data not shown). As
Cre was not expressed in all IgM+ cells (Fig. 3B), the 65%
maximum of observed recombination reflects >80% recombination
in Cre-expressing cells. This was confirmed by experiments on
mice carrying two floxed alleles. Both alleles in polβflox
Figure 4. Southern analyses of ligand-inducible, B cell-specific gene deletion in
mice. (A) Southern blot analysis of genomic DNA from B and T cells of mice
given daily i.p. injections of various doses of 4-OH-tamoxifen as indicated for
5 days. Genomic DNA was prepared from splenic B and T cells 1 day after the
last injection. Deletion of the polβflox allele was detected by Southern blot
analysis using a polβ-specific probe. The positions of the fragments derived from
the wild-type, loxP-flanked (floxed) and deleted polβ alleles and the percentages
of deletion of the floxed allele, as quantified with a Bio-Imaging Analyzer, are
indicated. Since ∼25% of B cells do not express Cre–EBD(G521R) (Fig. 3B),
64% recombination represents 85% recombination in Cre–EBD(G521R)-
expressing cells. (B) Reproducibility of Cre-mediated deletion of the loxP-flanked
DNA polymerase β (polβflox) allele in CreED-30 mice. Groups of two or three
mice were each treated with 0, 1, 2 or 4 mg as indicated. Injections and
quantifications were as in (C). Percent deletion (mean ± SD) of the floxed polβ
allele is presented in the histogram. (C) Kinetics of 4-OH-tamoxifen-inducible
gene deletion. CreED-30 mice were injected with 5 mg 4-OH-tamoxifen daily
for 1–5 days and analyzed 1 day after the last injection. (D) Analysis of
Cre-mediated deletion in homo- and heterozygous polβflox mice. Littermates
were injected with 4 mg 4-OH-tamoxifen daily for 4 days and were analyzed
1 day later. (E) Southern blot analysis of genomic DNA from various organs of an
untreated (left) or 4-OH-tamoxifen-treated mouse (daily i.p. injections of 5 mg
4-OH-tamoxifen for 4 days; right).
homozygotes showed percent induced recombination to the same
extent as the single allele in heterozygotes (Fig. 4D). A similar
degree of 4-OH-tamoxifen-inducible recombination was obtained in
B cells from mice harboring either a floxed allele of the
C-terminal src kinase gene (csk) or two heterozygotic floxed
alleles (polβ and csk; F.Schwenk, C.Schmedt and A.Tarakovsky,
unpublished results). We observe therefore that recombination
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can be induced in ∼80% of Cre-expressing B lymphocytes to the
same extent at one or two floxed loci. This suggests that no
recombination is inducible in the remaining 20% of Cre-positive
B lymphocytes as determined by FACS analysis (Fig. 3B),
possibly due to insufficient levels of Cre expression.
DISCUSSION
Contemporary analysis of gene function in mammals rests
predominantly on the technology of genomic manipulations of
mice. DNA delivery to mouse oocytes or embryonal stem cells
permits stable alteration of the mouse genome, however,
strategies of somatic mutagenesis are required so that gene
function can be studied in a chosen cell type at a chosen time.
Previous work to develop somatic mutagenesis in mice employed
site-specific recombination, either by restricting expression of
Cre activity to a chosen cell type (8–11) or in a variety of tissues
upon induction (7,18,19). Ideally, somatic mutagenesis should be
exclusively confined to a chosen place and time. We show here
a strategy that delivers this precision in B lymphocytes by
combining tissue-specific and ligand-dependent regulation.
These two regulatory modes were readily combined in a single
transgene. Consequently, precise somatic mutagenesis in B
lymphocytes was accomplished by use of a single effector mouse
line. The simplicity of the strategy recommends its use in other
applications. Other applications will require, as was the case here
for B lymphocytes, enhancer/promoter combinations that deliver
the desired tissue-restricted expression pattern at reasonable
expression levels. Currently there is an ongoing, collective effort
to establish a range of transgenic mouse lines that express Cre
recombinase in different tissues (http://www.mshri.on.ca/develop/
nagy/Cre.htm ). One outcome of this effort will be identification
of useful enhancer/promoter combinations for Cre expression in
restricted patterns in mice. We suggest that these Cre transgenes
are good candidates for the simple addition of the ∼1 kb DNA
fragment that encodes a steroid receptor LBD so that temporal
regulation can be added. It is also worth considering that addition
of a second level of regulation may overcome the occasional
problem of Cre recombinase transgene expression very early in
development. In such cases very early expression of Cre in
development can result in widespread, undesired deletion of the
floxed allele before the intended time and place. The additional level
of regulation conferred by inclusion of an LBD should help to
overcome this problem and thereby expand the repertoire of useful
enhancer/promoter combinations for Cre recombinase expression.
There have been three previous publications describing systems
of temporally regulated somatic mutagenesis in mice (7,18,19).
Either because of implicit strategy limitations or by choice, none
of these studies employed combinatorial use of temporal and
spatial regulation to enhance mutagenic precision. Consequently,
these approaches have been limited by unpredictable or unwanted
consequences of SSR expression in a range of different tissues. In
contrast, our combinatorial use of a tissue-specific transgene with
a Cre–EBD fusion protein permitted greater mutagenic precision,
thereby avoiding the complications inherent in widespread
recombination of differing efficiencies in many tissues.
Future developments with this strategy of somatic mutagenesis
should address two issues. First, we did not observe complete
recombination after induction in the chosen cell type. The
inability to induce complete recombination in a chosen cell
population represents a limitation to certain experiments, such as
those involving gene knock-outs of non-cell autonomous factors.
However, gain-of-function experiments or knock-outs with cell
autonomous factors do not require 100% recombination in the
target tissue. In the latter case the presence of a mixed population
of wild-type and recombined cells may offer the advantage of
allowing wild-type/mutant comparisons in the same animal. An
internal comparison can be varied by use of different ligand
administration regimes to generate populations displaying different
ratios of wild-type and recombined cells. Nevertheless, it would
clearly be desirable to express the SSR–LBD in 100% of the cell
type being investigated. In common with some other cases of
transgenesis generated by oocyte injection (20), the transgene
employed here appears to express in a mosaic fashion (Fig. 3B).
This problem may be avoidable by ‘knock-in’ strategies, where
the SSR–LBD is directed to an endogenous locus known to be
expressed in the desired cell-restricted manner (21).
Second, high doses of 4-OH-tamoxifen, or other estrogen
antagonists, were required for induction. This is because the G521R
mutation reduces β-estradiol binding by >10 000-fold, but also
reduces binding by the synthetic antagonists by ∼100-fold
(M.Nichols, J.M.J.Rientjes, and A.F.Stewart, unpublished results).
Furthermore, these estrogen antagonists will affect the endogenous
estrogen receptor. Although we did not observe any obvious
effect on adults or any change in lymphocyte populations at even
the highest doses administered here, antagonist action on the
endogenous estrogen receptor will significantly limit certain
applications, such as induction of recombination in utero (22).
Better ligand/steroid receptor pairs, ideally ones that are completely
independent of activities in mice, are needed to extend the
usefulness of LBD regulation.
The effective combination of spatial and temporal regulatory
modes presented here has implications for regulatory design in
other contexts. Since LBD regulation appears to function in all
eukaryotes (23–25), the combinatorial principle of this work is
broadly applicable, particularly to plants. Similarly, a combinatorial
approach in medicinal gene therapy could also be used to enhance
control of expression of the exogenous gene(s).
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